WHO ICTRP trial
A prospective, open-label, multicenter phase-II trial to evatuate the efficacy…
DRKS00007710 · German Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | DRKS00007710 |
|---|---|
| Public title | A prospective, open-label, multicenter phase-II trial to evatuate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib followed by ibrutinib and GA101 maintenance in CLL patients |
| Scientific title | A prospective, open-label, multicenter phase-II trial to evatuate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib followed by ibrutinib and GA101 maintenance in CLL patients - CLL2-BIG |
| Primary sponsor | Universität zu Köln |
| Registry | German Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Germany |
| Conditions | C91.1;Chronic lymphocytic leukaemia of B-cell type;C91.1 |
| Interventions | Group 1: Debulking: Two debulking cycles of bendamustine will be administered before induction with GA101 (obinutuzumab) and ibrutinib unless the patient has a contraindication or a debulking is not clinically indicated based on the… |
| Registration date | Sep 6, 2015 |
| Target size | 62 |
| Secondary IDs | EUCTR2014-000569-35-DE;2014-000569-35 |
| Registry page | drks.de |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: